SCHEMBL19793288

SCHEMBL19793288

O=C1CCCC(O)N1CCc1cnn2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.44
DRD3 P35462 9/20 0.42
DRD4 P21917 7/20 0.42
KCNH2 Q12809 1/20 0.40
DRD2 P14416 3/20 0.38
PER2 O15055 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EPHB3 P54753 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR1A P08908 1/20 0.35
DRD1 P21728 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17525756 0.79 DRD3 (0.51) HDAC1DRD3DRD4KCNH2DRD2
SCHEMBL19590974 0.68 HCRTR1 (0.35) PER2
SCHEMBL22538976 0.67 EPHX1 (0.40) KCNH2ALDH1A1
SCHEMBL20880100 0.67 HCRTR1 (0.53) DRD3DRD4DRD2ALDH1A1TSHR
SCHEMBL19793343 0.66 HCRTR2 (0.36)
SCHEMBL19793300 0.66 KDM4E (0.34) KCNH2KDM4EALDH1A1
SCHEMBL23587071 0.66 DRD3 (0.55) HDAC1DRD3DRD4KCNH2DRD2
SCHEMBL3793301 0.66 DRD3 (0.51) HDAC1DRD3DRD4KCNH2DRD2
SCHEMBL22538944 0.65 HRH3 (0.52)
SCHEMBL6612386 0.65 DRD3 (0.54) HDAC1DRD3DRD4DRD2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10196377-B2 Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) 2019-02-05 US disclosed
US-20180022728-A1 Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022728-A1 Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives GCDH, GLS, HADH HDAC1 1190/4885DRD3 4225/4885DRD4 4323/4885
US-10196377-B2 Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives GCDH, GLS, HADH HDAC1 1306/4885DRD3 4118/4885DRD4 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.